Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Modafinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Armodafinil SCHEMBL34489 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL1560974 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| (S)-Modafinil SCHEMBL1403524 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL34488 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3238686 | 0.95 | CYP2D6 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3908867 | 0.92 | EPHX1 (0.42) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL5031196 | 0.90 | CYP1A2 (0.39) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3914634 | 0.90 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL19025521 | 0.90 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| Modafinil SCHEMBL3921259 | 0.90 | PKM (0.41) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4718177-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-7405323-B2 | Modafinil polymorphic forms | CEPHALON FRANCE (FR) | 2008-07-29 | — | — | US | claimed |
| US-20060252835-A1 | treatment of sleep disorders with five novel polymorphic forms of modafinil racemate called CRL 40476 form III, CRL 40476 form IV, CRL 40476 form V, CRL 40476 form VI, CRL 40476 form VII; preparing a new solvate of modafinil comprising dissolving in solvent and crystallizing | CEPHALON FRANCE (FR) | 2006-11-09 | — | — | US | claimed |
| JP-2005535698-A | — | — | 2005-11-24 | — | — | JP | claimed |
| CN-1675177-A | Modafinil polymorphic forms | CEPHALON FRANCE (FR) | 2005-09-28 | — | — | CN | claimed |
| EP-1575915-A1 | MODAFINIL POLYMORPHIC FORMS | CEPHALON FRANCE (FR) | 2005-09-21 | — | — | EP | claimed |
| US-20040102523-A1 | Modafinil polymorphic forms | TEVA SANTE (FR) | 2004-05-27 | — | — | US | claimed |
| WO-2004014846-A1 | MODAFINIL POLYMORPHIC FORMS | CEPHALON FRANCE (FR) | 2004-02-19 | — | — | WO | claimed |
| CN-102875429-B | Modafinil polymorphic forms | CEPHALON FRANCE | 2014-12-10 | — | — | CN | disclosed |
| CN-101619033-B | Modafinil polymorphic forms | CEPHALON FRANCE | 2013-07-31 | — | — | CN | disclosed |
| CN-102875429-A | Modafinil polymorphic forms | CEPHALON FRANCE | 2013-01-16 | — | — | CN | disclosed |
| CN-102875430-A | Modafinil polymorphic forms | CEPHALON FRANCE | 2013-01-16 | — | — | CN | disclosed |
| EP-2402311-A1 | Modafinil polymorphic form VI | CEPHALON FRANCE (FR) | 2012-01-04 | — | — | EP | disclosed |
| US-7649020-B2 | Modafinil polymorphic forms | CEPHALON FRANCE (FR) | 2010-01-19 | — | — | US | disclosed |
| US-6992219-B2 | Modafinil polymorphic forms | CEPHALON FRANCE (FR) | 2006-01-31 | — | — | US | disclosed |
| CN-1675177-A | Modafinil polymorphic forms | CEPHALON FRANCE (FR) | 2005-09-28 | — | — | CN | disclosed |
| EP-1575915-A1 | MODAFINIL POLYMORPHIC FORMS | CEPHALON FRANCE (FR) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005077894-A1 | MODAFINIL COMPOSITIONS | CEPHALON, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20040102523-A1 | Modafinil polymorphic forms | TEVA SANTE (FR) | 2004-05-27 | — | — | US | disclosed |
| WO-2004014846-A1 | MODAFINIL POLYMORPHIC FORMS | CEPHALON FRANCE (FR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252835-A1 | treatment of sleep disorders with five novel polymorphic forms of modafinil racemate called CRL 40476 form III, CRL 40476 form IV, CRL 40476 form V, CRL 40476 form VI, CRL 40476 form VII; preparing a new solvate of modafinil comprising dissolving in solvent and crystallizing | CYP4F11, NR1D1, CYP4F3 | SLC6A3 302/4885CYP2D6 11/4885CYP1A2 160/4885 |
| US-20040102523-A1 | Modafinil polymorphic forms | GRIN3A, GRIN3B, COMT | SLC6A3 23/4885CYP2D6 51/4885CYP1A2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.